Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721656 | 0.78 | — | — | |
| SCHEMBL37815 | 0.75 | KDM4E (0.54) | TP53KDM4ELMNANPC1ALDH1A1 | |
| SCHEMBL1925074 | 0.73 | GOT1 (0.33) | GOT1TP53 | |
| SCHEMBL30792004 | 0.72 | GOT1 (0.46) | HDAC4GOT1DHODHHTR2CTP53 | |
| SCHEMBL1456807 | 0.72 | GOT1 (0.46) | HDAC4GOT1DHODHHTR2CTP53 | |
| SCHEMBL29442588 | 0.72 | GOT1 (0.46) | HDAC4GOT1DHODHHTR2CTP53 | |
| SCHEMBL1521688 | 0.72 | APLNR (0.31) | TP53KDM4ELMNANPC1ALDH1A1 | |
| SCHEMBL715745 | 0.72 | RAB9A (0.44) | TP53NPC1PKMHPGDRAB9A | |
| SCHEMBL969567 | 0.71 | — | — | |
| SCHEMBL115447 | 0.69 | CYP3A4 (0.33) | ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903364-A | Thiazoline urea and amide derivatives and methods of use thereof | ABBOTT LAB | 2010-12-01 | — | — | CN | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| CN-101815711-A | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | SCHERING CORP | 2010-08-25 | — | — | CN | claimed |
| EP-2155722-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| CN-110669052-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | ORION CORPORATION (FI) | 2003-08-21 | — | — | US | disclosed |
| CN-1418196-A | Pyridazinylphenylhydrazones for anti-congestive heart failure | ORION CORP (FI) | 2003-05-14 | — | — | CN | disclosed |
| CN-1418196-A | Pyridazinylphenylhydrazones for anti-congestive heart failure | ORION CORP (FI) | 2003-05-14 | — | — | CN | disclosed |
| EP-1265871-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068611-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2001-09-20 | — | — | WO | disclosed |
| EP-0008711-B1 | A METHOD OF PREPARING A 2-HYDROXY-3-ISOPROPYL OR A 2-HYDROXY-3-TERT-BUTYLAMINOPROPYL AROMATIC ETHER | SMITHKLINE BECKMAN CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| EP-0008711-A1 | A method of preparing a 2-hydroxy-3-isopropyl or a 2-hydroxy-3-tert-butylaminopropyl aromatic ether | SMITHKLINE BECKMAN CORPORATION (US) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | FABP3, TNNI3, TNNT2 | HDAC4 552/4885GOT1 1021/4885DHODH 4210/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | HDAC4 742/4885GOT1 1402/4885DHODH 2391/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | HDAC4 3731/4885GOT1 612/4885DHODH 2979/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | HDAC4 3731/4885GOT1 612/4885DHODH 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.